Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis
Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis
复制标题
DOI：
10.1177/1352458510362442
复制
发表时间：
2010-07-01
影响因子：
5.8
通讯作者：
Gasperini, Claudio
中科院分区：
文献类型：
--
作者：
De Stefano, Nicola;Curtin, Francois;Gasperini, Claudio
w 这项研究评估了皮下注射 (sc) 干扰素 (IFN)-β 1a 新制剂对复发缓解型多发性硬化症 (RRMS) 的疗效。患者 (n=180) 被随机 (2:1) 接受 IFN-β 1a 或安慰剂治疗 16 周；然后所有患者均接受 IFN-β 1a 治疗 24 周。每月进行脑部 MRI 检查。第 16 周时，IFN-β 1a 组的合并独特活动性 (CUA) 病变的平均数量低于安慰剂组（p < 0.001；病变减少 69%）。到第 4 周时，使用 IFN-β 1a 后，CUA 病变的平均累积数量已经较低（事后分析；p=0.015）。 sc IFN-β 1a 的新配方对 RRMS 的 MRI 结果具有快速有益的影响。
w This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta 1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n=180) were randomized (2:1) to IFN-beta 1a or placebo for 16 weeks; all patients then received IFN-beta 1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-beta 1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA lesions was already lower with IFN-beta 1a by week 4 ( post hoc analysis; p=0.015). The new formulation of sc IFN-beta 1a has rapid beneficial effects on MRI outcomes in RRMS.